We narrowed to 1,068 results for: aav

#157970-AAV.A08.T

Ready-to-use AAV2(4pMut)dHS in BSS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A03.T

Ready-to-use AAV2 in BSS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A02.T

Ready-to-use AAV2 in PBS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#241241-AAV5

Ready-to-use AAV5 particles produced from GfaABC1D-Lck-mCherry-ibARK (#241241). In addition to the viral particles, you will also receive purified GfaABC1D-Lck-mCherry-ibARK plasmid DNA. GfaABC1D-driven expression of Lck-mCherry-ibARK. These AAV preparations are suitable purity for injection into animals.

Jun Nagai

Dewa et al Nature. 2025 Oct 15. doi: 10.1038/s41586

Jan. 15, 2026

Academic Institutions and Nonprofits only

#203840-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-Kir2.1WT-2A-mScarlet-KASH (#203840). In addition to the viral particles, you will also receive purified pAAV-hSyn-Kir2.1WT-2A-mScarlet-KASH plasmid DNA. hSyn-driven expression of Kir2.1 and mScarlet-KASH. These AAV preparations are suitable purity for injection into animals.

Ivo Spiegel

Roethler et al Neuron. 2023 Jun 20:S0896-6273(23)00399-

Oct. 8, 2025

Academic Institutions and Nonprofits only

#213936-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiPVe4_dTomato_nlsdTomato (#213936). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the chandelier cell-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213856-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiVIPe4_ChR2_mCherry (#213856). In addition to the viral particles, you will also receive purified pAAV_BiVIPe4_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the VIP interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#183519-AAV8

Ready-to-use AAV8 particles produced from pAAV-CaMKIIa-ChRmine-oScarlet-KV 2.1-WPRE (#183519). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-ChRmine-oScarlet-KV 2.1-WPRE plasmid DNA. CaMKIIa-driven expression of ChRmine-oScarlet-KV 2.1. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Kishi et al Cell. 2022 Feb 17;185(4):672-689.e23. do

Dec. 18, 2024

Academic Institutions and Nonprofits only

#198516-AAV1

Ready-to-use AAV1 particles produced from pAAV_EF1a-DIO-PdCO-mScarlet-ER-miniWPRE (#198516). In addition to the viral particles, you will also receive purified pAAV_EF1a-DIO-PdCO-mScarlet-ER-miniWPRE plasmid DNA. Ef1a-driven, Cre-dependent expression of the optimized opsin PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only

#83894-AAV5

Ready-to-use AAV5 particles produced from pAAV-hDlx-Flex-dTomato-Fishell_7 (#83894). In addition to the viral particles, you will also receive purified pAAV-hDlx-Flex-dTomato-Fishell_7 plasmid DNA. hDlx-driven, Cre-dependent expression of dTomato. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Sept. 27, 2023

Academic Institutions and Nonprofits only

#104055-AAV2

Ready-to-use AAV2 particles produced from pAAV-CAG-eYFP (#104055). In addition to the viral particles, you will also receive purified pAAV-CAG-eYFP plasmid DNA. CAG-driven eYFP expression control. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

June 13, 2023

Academic Institutions and Nonprofits only

#83895-AAV8

Ready-to-use AAV8 particles produced from pAAV-hDlx-Flex-GFP-Fishell_6 (#83895). In addition to the viral particles, you will also receive purified pAAV-hDlx-Flex-GFP-Fishell_6 plasmid DNA. hDlx-driven, Cre-dependent expression of GFP. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

May 22, 2023

Academic Institutions and Nonprofits only

#117382-AAV2

Ready-to-use AAV2 particles produced from pAAV-hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified pAAV-hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

Feb. 14, 2022

Academic Institutions and Nonprofits only

#117382-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified pAAV-hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

Jan. 6, 2022

Academic Institutions and Nonprofits only

#203841-AAV2

Ready-to-use AAV2 particles produced from pAAV-hSyn-Kir2.1Mut-2A-mScarlet-KASH (#203841). In addition to the viral particles, you will also receive purified pAAV-hSyn-Kir2.1Mut-2A-mScarlet-KASH plasmid DNA. hSyn-driven expression of mutant murine Kir2.1 and mScarlet-KASH. These AAV preparations are suitable purity for injection into animals.

Ivo Spiegel

Roethler et al Neuron. 2023 Jun 20:S0896-6273(23)00399-

Feb. 9, 2026

Academic Institutions and Nonprofits only

#140275-AAV1

Ready-to-use AAV1 particles produced from pAAV-N-RAM-d2tTA-TRE-mKate2 (#140275). In addition to the viral particles, you will also receive purified pAAV-N-RAM-d2tTA-TRE-mKate2 plasmid DNA. RAM-containing and TRE-driven expression of mKate2. These AAV preparations are suitable purity for injection into animals.

Yingxi Lin

Sun et al Cell. 2020 Apr 16;181(2):410-423.e17. do

Jan. 15, 2026

Academic Institutions and Nonprofits only

#213833-AAV5

Ready-to-use AAV5 particles produced from pAAV_BiCHATe27_GCaMP6f (#213833). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the cholinergic neuron-targeting enhancer E27. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Nov. 13, 2025

Academic Institutions and Nonprofits only

#213945-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiSSTe4_ChR2_mCherry (#213945). In addition to the viral particles, you will also receive purified pAAV_BiSSTe4_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the SST interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213855-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiVIPe4_dTomato_nlsdTomato (#213855). In addition to the viral particles, you will also receive purified pAAV_BiVIPe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the VIP interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213818-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiSSTe10_GCaMP6f (#213818). In addition to the viral particles, you will also receive purified pAAV_BiSSTe10_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the SST interneuron-targeting enhancer E10. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only